ProMIS Neurosciences (PMN)
NASDAQ:PMN
Top Page
ProMIS Neurosciences
(NASDAQ:PMN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$12.00
▲(47.78% Upside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, ongoing cash burn, and negative equity in multiple years). A meaningful offset is the recent PIPE financing that improves runway and funds key clinical milestones, while technicals and valuation are mixed to weak.
Positive Factors
Extended runway via $75M PIPE
The $75M PIPE is structured to extend the company’s cash runway into 2028 and specifically fund completion of the Phase 1b PMN310 study plus mid‑ and 12‑month top‑line readouts in 2026. Securing milestone capital reduces near‑term financing risk and supports execution of key value-driving clinical programs.
Negative Factors
Persistent cash burn
Operating and free cash flows were negative in every reported year with a significant deterioration in 2025. Persistent cash burn forces recurring external financing, increases dilution risk, and reduces strategic flexibility if trials are delayed or costs rise, making long‑term planning contingent on capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended runway via $75M PIPE
The $75M PIPE is structured to extend the company’s cash runway into 2028 and specifically fund completion of the Phase 1b PMN310 study plus mid‑ and 12‑month top‑line readouts in 2026. Securing milestone capital reduces near‑term financing risk and supports execution of key value-driving clinical programs.
Read all positive factors
ProMIS Neurosciences (PMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.81M
Dividend YieldN/A
Average Volume (3M)819.50K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue GrowthN/A
EPS Growth-273.84%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.11
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$35.00Price Target Upside331.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-6.31
Revenue Forecast (FY)N/A
ProMIS Neurosciences Business Overview & Revenue Model
Company Description
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes...
How the Company Makes Money
null...
ProMIS Neurosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Gross Profit | 0.00 | 0.00 | -10.44M | 0.00 | ― |
| EBITDA | -40.17M | 2.86M | -17.81M | -17.77M | -9.33M |
| Net Income | -39.72B | 2.78M | -17.51M | -18.06M | ― |
Balance Sheet | |||||
| Total Assets | 9.18B | 18.91M | 13.62M | 9.38M | 22.44M |
| Cash, Cash Equivalents and Short-Term Investments | 6.15M | 13.32M | 12.63M | 8.01M | 21.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 4.94M |
| Total Liabilities | 10.44B | 2.42M | 9.87M | 11.20M | 15.28M |
| Stockholders Equity | -1.26M | 16.49M | 3.75M | -1.82M | 7.16M |
Cash Flow | |||||
| Free Cash Flow | -28.12B | -27.18M | -10.84M | -17.04M | -9.45M |
| Operating Cash Flow | -28.12B | -27.18M | -10.84M | -17.03M | -9.44M |
| Investing Cash Flow | -702.00K | -693.00 | -1.35K | -1.98K | 95.93K |
| Financing Cash Flow | 20.94B | 27.88M | 17.75M | 6.49M | 25.63M |
ProMIS Neurosciences Technical Analysis
Neutral
8.12
Price Trends
16.78
Negative
12.62
Positive
12.76
Positive
Market Momentum
-1.65
Positive
40.81
Neutral
52.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Neutral. The current price of 8.12 is below the 20-day moving average (MA) of 14.75, below the 50-day MA of 16.78, and below the 200-day MA of 12.76, indicating a neutral trend. The MACD of -1.65 indicates Positive momentum. The RSI at 40.81 is Neutral, neither overbought nor oversold. The STOCH value of 52.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PMN.
ProMIS Neurosciences Risk Analysis
ProMIS Neurosciences disclosed 76 risk factors in its most recent earnings report. ProMIS Neurosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProMIS Neurosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $27.81M | -0.30 | 9999.00% | ― | ― | -273.84% | |
44 Neutral | $246.66M | -0.12 | 506.72% | ― | ― | -323.61% | |
44 Neutral | $47.07M | -2.46 | -159.43% | ― | ― | 62.84% | |
41 Neutral | $25.13M | -1.76 | ― | ― | ― | 31.09% | |
40 Underperform | $6.29M | -1.04 | -49.00% | ― | 47.17% | 26.84% |
* Healthcare Sector Average
PMN
ProMIS Neurosciences
12.05
-1.95
-13.93%
NERV
Minerva Neurosciences
5.87
4.40
297.97%
IMRN
Immuron
0.85
-0.88
-50.87%
ANVS
Annovis Bio
1.73
0.51
41.80%
NRSN
Neurosense Therapeutics Ltd.
0.71
-0.35
-33.02%
ProMIS Neurosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
ProMIS Neurosciences Announces $75 Million PIPE Financing
Positive
Jan 30, 2026
On January 30, 2026, ProMIS Neurosciences announced it had entered into a private investment in public equity financing, signing a securities purchase agreement on January 29, 2026 with new and existing institutional and accredited investors to ra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.